SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

Leukemia. 2012 Aug;26(8):1892-5. doi: 10.1038/leu.2012.67. Epub 2012 Mar 9.

Authors

Z-X Cao, J-J Liu, R-L Zheng, J Yang, L Zhong, Y Xu, L-J Wang, C-H Zhang, B-L Wang, S Ma, Z-R Wang, H-Z Xie, Y-Q Wei, S-Y Yang

PMID: 22402607
DOI: 10.1038/leu.2012.67

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cell Line, Tumor
Cell Proliferation / drug effects
ErbB Receptors / antagonists & inhibitors*
ErbB Receptors / genetics
ErbB Receptors / metabolism
Humans
Inhibitory Concentration 50
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics*
Mutation
Phosphorylation / drug effects
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / pharmacology*
Proto-Oncogene Proteins c-abl / antagonists & inhibitors*
Proto-Oncogene Proteins c-abl / genetics
Proto-Oncogene Proteins c-abl / metabolism
Purines / pharmacology*
Xenograft Model Antitumor Assays
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*
fms-Like Tyrosine Kinase 3 / genetics
fms-Like Tyrosine Kinase 3 / metabolism

Substances

Protein Kinase Inhibitors
Purines
SKLB1028
ErbB Receptors
fms-Like Tyrosine Kinase 3
Proto-Oncogene Proteins c-abl